Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of LY3305677 in Participants With Type 2 Diabetes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03928379
Recruitment Status : Not yet recruiting
First Posted : April 26, 2019
Last Update Posted : August 20, 2019
Sponsor:
Information provided by (Responsible Party):
Eli Lilly and Company

Brief Summary:
The main purpose of this study is to learn more about the safety and side effects of LY3305677 when it is given as an injection just under the skin to participants with type 2 diabetes. The study will last about 20 weeks for each participant, not including screening.

Condition or disease Intervention/treatment Phase
Diabetes Mellitus, Type 2 Drug: LY3305677 Drug: Placebo Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 48 participants
Allocation: Randomized
Intervention Model: Sequential Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Basic Science
Official Title: A Multiple-Ascending Dose Study in Patients With Type 2 Diabetes Mellitus to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3305677
Estimated Study Start Date : October 1, 2019
Estimated Primary Completion Date : August 18, 2020
Estimated Study Completion Date : August 18, 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: LY3305677
LY3305677 administered SC
Drug: LY3305677
Administered SC

Placebo Comparator: Placebo
Placebo administered SC
Drug: Placebo
Administered SC




Primary Outcome Measures :
  1. Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug [ Time Frame: Baseline through 20 weeks ]
    A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module


Secondary Outcome Measures :
  1. Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of LY3305677 [ Time Frame: Baseline through 48 hours postdose ]
    PK: Cmax of LY3305677

  2. PK: Area Under the Concentration-Time Curve (AUC) of LY3305677 [ Time Frame: Baseline through 48 hours postdose ]
    PK: AUC of LY3305677

  3. Pharmacodynamics (PD): Change from Baseline in Fasting Plasma Glucose [ Time Frame: Baseline, through Week 12 ]
    PD: Change from Baseline in Fasting Plasma Glucose

  4. PD: Change from Baseline in Fasting Plasma Insulin [ Time Frame: Baseline, through Week 12 ]
    PD: Change from Baseline in Fasting Plasma Insulin



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years to 69 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Have Type II diabetes
  • Body mass index (BMI) of 25-40 kilograms per square meter (kg/m²), inclusive
  • Have a body weight of <150 kilograms (kg)
  • Have clinical lab test results within normal reference range for the population or investigator site, or results with acceptable deviations that are judged to be not clinically significant by the investigator; however, should have serum magnesium and potassium levels, along with lactate dehydrogenase, CK values within the normal range at screening and Day -2.

Exclusion Criteria:

  • Have Type 1 diabetes or latent autoimmune diabetes in adults
  • Have uncontrolled diabetes defined as an episode of ketoacidosis or hyperosmolar state requiring hospitalization for 6 months prior to screening
  • Have had an episode of severe hypoglycemia, defined by the occurrence of neuroglycopenic symptoms requiring the assistance of another person for recovery, within 6 months prior to Visit 1
  • Have an abnormal 12-lead electrocardiogram (ECG) at screening and/or Day -2 that, in the opinion of the investigator, increases the risks associated with participating in the study or may confound ECG data analysis
  • Have poorly controlled hypertension at screening; or a change in antihypertensive medication within 30 days of screening
  • Have an estimated glomerular filtration rate <45 milliliters per minute per 1.73 meters squared of body surface area (mL/min/1.73 m²)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03928379


Contacts
Layout table for location contacts
Contact: There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 ClinicalTrials.gov@lilly.com

Locations
Layout table for location information
Germany
Profil Institut für Stoffwechselforschung Not yet recruiting
Neuss, Nordrhein-Westfalen, Germany, 41460
Contact    492131155402      
Principal Investigator: Jorge Arrubla         
Sponsors and Collaborators
Eli Lilly and Company
Investigators
Layout table for investigator information
Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) Eli Lilly and Company

Layout table for additonal information
Responsible Party: Eli Lilly and Company
ClinicalTrials.gov Identifier: NCT03928379     History of Changes
Other Study ID Numbers: 17011
I8P-MC-OXAD ( Other Identifier: Eli Lilly and Company )
2018-004779-11 ( EudraCT Number )
First Posted: April 26, 2019    Key Record Dates
Last Update Posted: August 20, 2019
Last Verified: August 17, 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes

Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases